*nlm.life
			PubMed Journals: Clin Exp Immunol

  Source:		PMID: 30993689


    		Clin Exp Immunol. 2019 May;196(2):155-156.
     		doi: 10.1111/cei.13303.

			Vaccines for emerging pathogens: from research
			to the clinic.

			Williamson ED(1).

			Author Information
			(1) Defence Science and Technology Laboratory,
			Porton Down, Salisbury, UK.

			In this two-part series of reviews, we have
			invited experts in their fields to contribute
			articles on the status of vaccine research
			and development for emerging pathogens. This
			topic has been brought into sharp focus
			in recent years following significant outbreaks
			of viral diseases such as those causing
			severe acute respiratory syndrome and
			Middle East respiratory syndrome, as well
			as devastating outbreaks of diseases caused by
			the Ebola, Marburg, Zika and Lassa fever
			viruses, to name only a few examples. Additionally,
			bacterial infections leading to bubonic
			and pneumonic plague, most notably in Madagascar
			in 2018, as well as malaria in many tropical countries,
			melioidosis in south east Asia and tularaemia
			in northern Europe and North America, have
			incurred significant morbidity and mortality.
			In this review series, the life cycle of
			these pathogens and the epidemiology of
			disease have been reviewed in the context
			of potential points of intervention for
			the prevention of human infection. Many
			of the emerging pathogens are zoonoses and,
			as such, there is scope for intervention
			at the animal/insect/environmental reservoir. Other pathogens
			covered in this review series are considered
			to be re-emerging, such as
			multi-drug resistant tuberculosis.

			© 2019 Crown copyright. Clinical and Experimental
			Immunology © 2019 British Society for Immunology.
			This article is published with the permission
			of the Controller of HMSO and the Queen's
			Printer for Scotland.

			DOI: 10.1111/cei.13303 PMCID: PMC6468174
			PMID: 30993689

     			                         Tweet       Print